Aryl Trehalose Derivatives as Vaccine Adjuvants for Mycobacterium tuberculosis.

ABSTRACT: Mycobacterium tuberculosis (Mtb) continues to be a major health threat worldwide, and the development of Mtb vaccines could play a pivotal role in the prevention and control of this devastating epidemic. Th17-mediated immunity has been implicated in disease protection correlates of immune protection against Mtb. Currently, there are no approved adjuvants capable of driving a Th17 response in a vaccine setting. Recent clinical trial results using trehalose dibehenate have demonstrated a formulation-dependant proof of concept adjuvant system CAF01 capable of inducing long-lived protection. We have discovered a new class of Th17-inducing vaccine adjuvants based on the natural product Brartemicin. We synthesized and evaluated the capacity of a library of aryl trehal

SUBMITTER: Ryter KT 

PROVIDER: S-EPMC6952572 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature